Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Aug 25, 2021

CBC-Led Consortium Buys Bain’s Hugel Stake For $1.5 Billion

STOCKS IN THIS STORY
Goenka Business & Finance Ltd.
--
Cosco (India) Ltd.
--
Nifty Capital Markets
--
Nifty Top 20 Equal Weight
--
MSCI World
--
Pritika Auto Industries Ltd
--
MSCI AC Asia ex-Japan
--
Nifty BHARAT Bond Index - April 2033
--
BSE Oil & Gas
--
BSE Finance
--
BNK Capital Markets Ltd.
--
BSE Healthcare
--

South Korean cosmetic pharmaceutical company Hugel Inc. said its largest investor, Bain Capital, has signed a deal to sell a 46.9% stake to a consortium led by private equity firm CBC Group.

The deal, one of the largest medical aesthetics transactions in Asia, is worth around 1.7 trillion won ($1.5 billion), including convertible bonds, Seoul-based Hugel said in a statement Wednesday. Abu Dhabi-based investment company Mubadala and South Korea's IMM Investment Corp. and GS Holdings Corp. are also part of the bidding group, the filing shows, confirming an earlier report by Bloomberg News.

Hugel shares tumbled as much as 9% in early Seoul trading Wednesday after the announcement. GS Holdings rose 0.91% as of 11:04 a.m. local time. 

The South Korean company mainly produces beauty goods including botulinum toxin, commonly known as botox, and hyaluronic acid filler, its website shows. It also makes cosmetics and medical devices.

Hugel's Botox product ‘Letybo' was approved by China's drug regulator in October 2020 after it filed an application in 2019. It is the fourth Botox product approved by China, where the aesthetic-medicine market is set to reach 31.5 billion yuan ($4.9 billion) in revenue by 2023, according to a Deloitte report. Hong Kong-listed Sihuan Pharmaceutical Holdings is currently the sole agent for Letybo in China.

The acquisition is healthcare buyout fund CBC's first move into the medical aesthetics sector. The Singapore-based firm invests across sectors including biopharmaceuticals, medtech and services, including Hong Kong-listed Everest Medicines Ltd. and Nasdaq-listed I-Mab.

“This marks the beginning of CBC's journey into the global medical aesthetics sector, in addition to our current pharma, medtech and services exposure,” the firm's Managing Director Michael Keyoung said in a statement. 

©2021 Bloomberg L.P.

With assistance from Bloomberg

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search